Polyrizon Achieves 94.6% Nasal Deposition for Naloxone Versus 79.6%
Polyrizon’s naloxone formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate, compared with 79.6% for the commercial reference, using a validated silicone cast model. It also reduced lower turbinate deposition to 5.4% versus 20.4%, potentially enhancing dosing consistency and systemic absorption speed.
1. Study Results
Polyrizon conducted a comparative evaluation of its naloxone intranasal formulation using a Koken® LM-005 silicone nasal cast model and quantitative image analysis. The formulation delivered 94.6% (±4.0%) deposition in the highly vascularized vestibule and upper turbinate, significantly outperforming the 79.6% (±3.0%) achieved by the commercial reference.
2. Deposition Advantages
The proprietary Trap & Target™ technology also minimized lower turbinate deposition to 5.4% versus 20.4% for the reference, which may reduce posterior runoff and improve dosing consistency. Enhanced targeting of the anterior nasal region suggests faster systemic uptake and higher bioavailability potential for intranasal drugs.
3. Development Outlook
Polyrizon plans to advance its naloxone program into further preclinical stages as part of its broader intranasal platform strategy. The company will leverage these results to support upcoming formulation optimization and prepare for regulatory discussions.